Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM149PT | TNBC | Basal B | Bosutinib | Src | nRTK | 0.16 | uM | 11937.145 | 0.9016 | 0.9142 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Bosutinib | Src | nRTK | 0.8 | uM | 11937.145 | 0.4691 | 0.4516 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Bosutinib | Src | nRTK | 4 | uM | 11937.145 | 0.1667 | -0.0634 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Bosutinib | Src | nRTK | 20 | uM | 11937.145 | 0.0068 | -0.7581 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Bosutinib | Src | nRTK | 100 | uM | 11937.145 | 0.0024 | -0.8457 | 2.3618 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 0.000256 | uM | 11057.145 | 0.9359 | 0.9657 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 0.00128 | uM | 11057.145 | 0.9850 | 0.9921 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 0.0064 | uM | 11057.145 | 1.0459 | 1.0236 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 0.032 | uM | 11057.145 | 0.9819 | 0.9905 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 0.16 | uM | 11057.145 | 0.9350 | 0.9652 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 0.8 | uM | 11057.145 | 0.6149 | 0.7613 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 4 | uM | 11057.145 | 0.2622 | 0.4096 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 20 | uM | 11057.145 | 0.0011 | -0.6605 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Bosutinib | Src | nRTK | 100 | uM | 11057.145 | 0.0020 | -0.6071 | 3.8266 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 12269.145 | 0.9766 | 0.9056 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 12269.145 | 0.9595 | 0.8380 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 12269.145 | 1.3044 | 2.4425 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 12269.145 | 1.2695 | 2.2565 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 12269.145 | 1.4352 | 3.1847 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 12269.145 | 1.0030 | 1.0121 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 4 | uM | 12269.145 | 0.7936 | 0.2470 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 20 | uM | 12269.145 | 0.8477 | 0.4269 | 0.4894 | |
| SUM185PE | TNBC | Luminal | Bosutinib | Src | nRTK | 100 | uM | 12269.145 | 1.0502 | 1.2107 | 0.4894 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 10579.145 | 0.8983 | 0.8086 | 1.0664 | |
| SUM225CWN | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 10579.145 | 0.8851 | 0.7838 | 1.0664 |